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Detection of Early Antiangiogenic Effects in Human Colon
Adenocarcinoma Xenografts: In vivo Changes of Tumor
Blood Volume in Response to Experimental VEGFR
Tyrosine Kinase Inhibitor
Young Ro Kim, Anna Yudina, JoseLuis Figueiredo, Wilfried Reichardt, Dana Hu-Lowe,
Alexander Petrovsky, Hye Won Kang, Denise Torres, Umar Mahmood,
Ralph Weissleder, and Alexei A. Bogdanov, Jr.
Center for Molecular Imaging Research, Massachusetts General Hospital, Charlestown, Massachusetts
Abstract
Antiangiogenesis is emerging as efficient strategy for targeting
and potentially eliminating neoplastic tumor vessels. The
main goal of this study was to establish whether absolute
tumor blood volume (Vb) change could be used as an early
predictor of antiangiogenesis in ectopic and orthotopic colon
carcinomas. To assess therapy-induced changes of Vb, we did
comparative analysis of signal intensities in tumors and
muscle using steady-state magnetic resonance imaging (MRI)
assisted with an intravascular paramagnetic contrast agent
[gadolinium-labeled protected graft copolymer (PGC-Gd)].
Athymic mice with implanted human MV522 tumors were
treated with vascular endothelial growth factor type 2
receptor tyrosine kinase inhibitor (VEGFR2-TKI) that has
been shown to inhibit VEGFR2 phosphorylation and tumor
growth in vivo . Animals were imaged either after a single day
or after a 1-week course of treatments. The measured Vb in
ectopic tumors was 2.5 F 1.5% of total tissue volume 1 week
after the implantation (n = 8). Two doses of VEGFR2-TKI
(25 mg/kg, p.o., b.i.d.) resulted in a decrease of Vb to 1.3 F
0.3%. In orthotopic tumors, the measured Vb was initially
higher (11.9 F 2.0%); however, VEGFR2-TKI treatment also
resulted in a statistically significant decrease of Vb. The
absolute Vb was not affected in the muscle as a result of
treatments. MRI measurements were corroborated by using
isotope and correlative histology experiments. Our results
show that steady-state MRI is highly sensitive to early
antiangiogenic effects caused by small molecule drugs. (Cancer
Res 2005; 65(20): 9253-60)
Introduction
Vascular endothelial growth factor (VEGF) type 2 receptor
(VEGFR2, Flk-1/KDR) is one of the major regulators of vasculo-
genesis and angiogenesis. The detailed analysis of the role of
VEGFR2-mediated signal transduction suggested that the inhib-
ition of VEGFR pathway would provide a powerful antiangiogenic
signal that could be highly useful in inhibiting pathogenic
angiogenesis (e.g., in cancer progression). The first anti-VEGF
targeted drug (bevacuzimab, Genentech, Inc., San Francisco, CA)
has already been approved in combination with the first-line
chemotherapy for treating metastatic colorectal cancer (reviewed
in ref. 1).
To date, several small molecule VEGFR2 kinase (KDR) inhibitors
have been tested in animal cancer models and resultant changes in
tumor vasculature have been described. Strong antiangiogenic
responses induced by SU5416 and SU6668 were previously shown
(2, 3). Decrease in tumor vascular density and vessel diameter and
higher blood flow in remnant tumor vessels were typical drug-
induced effects observed in animal models of cancer. Strong
antimetastatic and antiproliferative responses resulting in tumor
and endothelial cell apoptosis were reported (4). Similar findings of
reduced microvascular density, blood flow changes, as well as
inhibition of VEGF-mediated vascular permeability have been
reported after treating animals with SU11248 (5), PTK787/ZK
222584 (6, 7), CGP 41251 (8), and protein kinase C (PKC) 412 (9).
Some of the above inhibitors had variable selectivities and at least
partially blocked platelet-derived growth factor (PDGF)-h– and
PKC-mediated signal transduction. Recently, an experimental
VEGFR inhibitor, AG013736 (Pfizer, La Jolla, CA), showed efficient
endothelial cell regression with a 70% decrease of vascular density
in experimental tumors (10).
Noninvasive in vivo magnetic resonance imaging (MRI) of
antiangiogenic effects (11, 12) was instrumental in many of the
above studies (reviewed in refs. 13–16). The principal advantages of
noninvasive MRI are that (a) high anatomic resolution images
could be acquired repeatedly; (b) no ionizing radiation could affect
therapy assessment in preclinical studies; (c) the measurements are
done throughout the total tumor volume and provide global rather
than regional data; and (d) the results of antiangiogenic treatments
could be potentially detected at the early phase of the treatment.
The changes in tumor blood volume and flow detectable with MRI
in many cases precede gross morphology changes that result from
long-term effects of antiangiogenic treatment.
The changes in tumor blood volume can be assessed by several
fundamentally different MRI techniques. Intravascular T1 agents
(i.e., predominantly affecting longitudinal relaxation of proton
magnetization; ref. 17) enable quantifying the absolute blood
volume fraction (18). The probes affecting T2 relaxation [i.e.,
agents affecting spin-spin relaxation of water proton magnetiza-
tion, e.g., a bolus of paramagnetic chelate (19) or super-
paramagnetic nanoparticles (20)], allow Vb measurements by
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the dephased proton population (21). In general, signal intensity
enhancement created by intravascular T1 agents is usually
regarded as being affected by blood volume and intravascular-
extravascular water exchange. On the other hand, the signal
intensity reduction caused by a T2 contrast agent depends on
blood volume and geometry of vasculature (i.e., vessel radius; ref.
22). When compared with the T2 technique, the method using
T1 relaxation provides means to calculate the absolute blood
volume independently of geometric factors if a strictly intravas-
cular paramagnetic probe is used under valid water proton
exchange conditions (23). In addition, spectroscopic imaging of
tumor blood volume utilizing fluorine-19 nuclear MRI was also
found feasible (24).
The goal of this study was to determine whether inhibition of
VEGFR2-mediated signaling results in early changes of tumor
blood volume that could be measured with high precision using a
steady-state contrast-enhanced MRI (23, 25). Therefore, we set
forth to evaluate early response to the experimental VEGFR2
kinase indazole inhibitor AG013925 (Pfizer) in MV522 human colon
carcinoma-bearing mice. A radionuclide-based method was then
used to correct blood volume data, followed by a histologic
characterization of tumors to determine the influence of antiangio-
genesis on cell survival. Antiangiogenic effects were initially
investigated in s.c. (ectopic) MV522 tumor models, followed by
the verification of treatment effects in a high-resolution study of
orthotopic tumors implanted in the colon.
Materials and Methods
Cell culture. Human MV522 colon carcinoma cells were supplied by
Pfizer Global Research and Development (La Jolla, CA) and propagated in
10% fetal bovine serum, RPMI (Cellgro, Mediatech, Washington, DC). Red
fluorescent MV522 cell line stably expressing DsRed2 (MV522-DsRed2) was
obtained as described in ref. 26.
Imaging agent. Protected graft copolymer bearing covalently linked
gadolinium-diethylenetriaminepentaacetic acid residues (PGC-Gd) was
synthesized and purified as described before (27, 28). The batches of
PGC-Gd were characterized on size-exclusion high-performance liquid
chromatography column (TSK3000SW, Supelco, Bellefonte, PA) and
gadolinium concentrations were determined by the elemental analysis.
The polymer was dissolved at 50 mg/mL (13 mmol/L Gd) in Dulbecco’s PBS
(pH 7) and sterile filtered.
Fluorescent probes. Anti-digoxigenin F(abV)2 fragment (Roche Diagnos-
tics, Indianapolis, IN) was labeled with Cy3-monohydroxysuccincimide ester
(Amersham Biosciences, Piscattaway, NJ; ref. 26). Tomato (L. esculentum)
lectin was labeled using Alexa Fluor 488-hydroxysuccinimide ester
(Molecular Probes Inc., Eugene, OR). Fluorescent conjugates were purified
using Bio-Spin P-30 columns (Bio-Rad, Hercules, CA).
Tumor models. The procedures below were approved by the
Massachusetts General Hospital Animal Care and Use Committee. Colon
carcinoma xenografts were grown ectopically in athymic mice (nu/nu , 6 to
8 weeks old, 20 to 25 g, Massachusetts General Hospital Radiation
Oncology breeding facilities) as described in refs. 29, 30. Briefly, MV522
cells were harvested 1 day after reaching monolayer density. Two million
cells in 100 AL of serum-free cell culture medium were injected s.c. in
lower flanks of the mice. Seven days after the implantation of cells,
animals with tumors of an average size of f4 mm in diameter were
divided into two groups (treatment and control). Control animals received
0.5% carboxymethylcellulose (CMC) placebo (group 1, n = 3), whereas
treated animals received two doses of 25 mg/kg AG013925 homogenized
in 0.5% CMC p.o. b.i.d. (group 2, n = 3, delay between doses: 12 hours).
Tumor volumes were determined using caliper method. Additional groups
of animals underwent a long-term treatment with the inhibitor for 6 to
8 days (12-16 treatments; group 4, n = 3) and compared with a control
group, which received placebo only for 6 to 8 days (group 3, n = 3). A total
of three independent experiments were done (total n = 36 mice). On the
completion of treatment schedule, the animals were subjected to MRI (see
below).
For orthotopic implantation, the peritoneal cavity was surgically
exposed, the descendent colon was isolated, and 2  106 MV522-DsRed2
cells suspended in 20 AL HBSS were injected into the colon wall under
direct visualization with the aid of a dissecting microscope. Three weeks
postimplantation, colon tumor growth was verified by fluorescence
colonoscopy as described in ref. 31. After the tumor was localized using
visible and fluorescent light, animals were divided into two groups (n = 4,
each group) and treated with VEGFR2-TKI or placebo as described above.
The treatment was followed by a high-resolution MRI on 9.4T Bruker
instrument (see below).
Magnetic resonance imaging of mice and data analysis. Mice were
anesthetized using an i.p. injection of ketamine (80 mg/kg) and xylazine
(9 mg/kg) and placed on top of a plastic flask filled with warm water to
reduce imaging artifacts and to maintain normal mouse body temperature.
Custom-made 30-G catheters were inserted into the tail vein and attached
to a microheparin/saline flush. Anesthetized mice were placed prone with
tumors located at the center of a 3-in. surface coil and covered with
thermoinsulating sheet to prevent hypothermia. MRI data were collected
using a 1.5-T Signa scanner (General Electric Medical Systems, Milwaukee,
WI) and a three-dimensional spoiled gradient recalled (SPGR) pulse
sequence. First, a pre-contrast image was obtained followed by a post-
contrast image after the i.v. injection of PGC-Gd (50 Amol Gd/kg in 0.1 mL
saline). For Vb measurements, magnetic resonance images (matrix = 256 
256; 28 transverse slices, slice thickness = 0.7 mm) were collected with TR/
TE = 30/4.1 ms and flip angles = 40j, 60j, and 80j and field of view of 10 cm.
The entire MRI protocol required 45 minutes. Measurement errors due to
blood inflow at both edges of imaging slab were avoided by collecting the
data only at the central slices. The pre- and post-contrast agent MRI signal
intensities in the blood were measured in large vessels (f40-60 voxels were
measured across the central slices). Region-of-interest selection and the
analysis of time course of magnetic resonance signal data were made using
AFNI shareware package (32). Longitudinal relaxation time (T1) in the
blood was calculated by fitting the experimental blood signal intensity
dependence of three-dimensional fast SPGR pulse sequence parameters
using Matlab software (The Mathworks, Inc., Natick, MA). Imaging of mice
with orthotopic colon tumors was done as above except that 9.4T Bruker
system was used and the matrix and slice thickness were 256  256 and 0.5
mm with TR/TE = 40/5.5 ms, respectively. Additional spin-echo images were
acquired with matrix = 512  512, slice thickness = 0.5 mm, and TR/TE =
3,000/30 ms. Animals were maintained at 37jC under isoflurane anesthesia.
Tissue blood volume (Vb) was calculated as follows:
Vb ¼ ðSI post tissue  SI pre tissueÞ=ðSI post blood  SI pre bloodÞ ð1Þ
where SIpost_tissue and SIpost_blood indicate signal intensities measured in
tissue or the blood, respectively, after the administration of contrast agent
(PGC-Gd); SIpre_tissue and SIpre_blood indicate signal intensities measured in
tissue or the blood, respectively, before the administration of the above
contrast agent.
The calculation of Vb using this formula was valid assuming (a) near-
constant concentration of PGC-Gd in the blood during the first 45 minutes
after the i.v. administration (25, 27); (b) the complete exclusion of PGC from
RBC; (c) fast exchange of water across the RBC plasma membrane; and (d)
slow water exchange across endothelial barrier. The effects of water
exchange rate on blood volume depend on MRI pulse sequence parameters.
Therefore, the measured dependence of blood volume on pulse sequence
parameters was used to assess water exchange rates across the vascular
barrier as described previously (23, 33).
Radioisotope study. RBC content of tumoral and muscle blood supplies
was accounted for in an isotope study using RBC labeled using UltraTag kit
(Mallinckrodt Medical, St. Louis, MO) designed for ex vivo labeling of
erythrocytes with 99mTc pertechnetate. RBCs were isolated from 1 to 1.5 mL
of blood obtained from a syngeneic mouse. The total blood was then used
Cancer Research
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for labeling according to the instructions provided by the manufacturer
(1 mCi 99mTc/labeling reaction). The 99mTc-labeled RBCs were purified using
Hypaque-1077 (Sigma Chemical Co., St. Louis, MO) density centrifugation
followed by washing in HBSS. Two separate groups of mice (9 treated and
12 control as described above) were used in these experiments. A total
of 100 ACi of 99mTc were injected i.v. in the tail veins of 9 treated and
12 control mice. After 10 minutes postinjection, tumors and muscle samples
were surgically obtained from anesthetized mice. Visible blood vessels were
immediately electrocoagulated using a bipolar instrument (Elmed 50/Micro
output, Addison, IL) to prevent blood loss from tissues. Blood samples
(10-20 AL) were then withdrawn using cardiac puncture and 99mTc
radioactivity was determined using Wallac 1480 g-counter (Perkin-Elmer,
Wellesley, MA) calibrated using 99mTc standards. Quantitation of hema-
tocrits in individual tissues has been accomplished by using mouse blood
standards and assuming negligible immediate changes in hematocrit as a
result of i.v. injection of labeled RBC/PGC mixture.
Correction of Vb values. We assumed that longitudinal relaxation time
(T1) of the whole blood is affected by RBC volume fraction due to the fact
that intravascular contrast agents are distributed almost exclusively in
plasma. The blood volume values obtained during the MRI studies were
corrected for local differences in RBC content as described in the
Supplementary data.
Histology. H&E staining of parallel sections was done using standard
protocols. Colon samples were frozen cut after the lumena of the dissected
fragments were filled with HistoPrep (Fisher Scientific, Pittsburgh, PA).
To assess potential permeability of tumor blood vessels to agents with
hydrodynamic diameters similar to that of PGC, several animals were
injected with monocrystalline iron oxide nanoparticles (diameter, 20 nm;
ref. 34) 20 minutes before euthanasia. Tumors were frozen and 10 Am
sections were cut and stained using Perl’s stain (Prussian blue reaction) for
iron. Staining of endothelial cells in tumors was done by using anti-CD31
antibodies (rat anti-mouse monoclonal, MEC13.3, BD PharMingen, San
Diego, CA) labeled with digoxigenin. Binding of antibodies was visualized
using anti-digoxigenin F(abV)2 conjugated with alkaline phosphatase (Roche
Diagnostics). Tumor samples for fluorescence microscopy were prepared as
in ref. 26 with modifications. Tumor-bearing mice were preinjected with
Alexa 488–labeled tomato lectin (50-80 Ag/animal in 100 AL of saline) at
15 minutes before euthanasia. Tumors were excised, frozen, and cut into
8 Am sections. Genomic DNA fragmentation in was assessed using terminal
deoxyribonucleotidyl transferase–mediated dUTP nick end labeling
(TUNEL; ApopTag, Intergen, Purchase, NY) and Cy3-labeled antidigoxigenin
F(abV)2 (Roche Diagnostics). Fluorescence microscopy has been done using
Zeiss Axiovert 100 TV (Wetzlar, Germany) fitted with appropriate filter sets
(Omega Optical, Brattleboro, VT). Images were acquired using Cool-
SnapHQ-M CCD (Photometrics, Tucson, AZ) and processed using IP
LabSpectrum software (Signal Analytics, Vienna, VA).
Results
Tumor volume, vascular volume, and magnetic resonance
imaging of antiangiogenesis. Tumor volumes were monitored
using traditional caliper method and MRI. Caliper measurements
showed no relative decrease of tumor volume in animals treated
with two doses of VEGFR2-TKI versus placebo (Fig. 1A). The
difference in tumor volumes was evident only in groups 3 and 4
treated for 7 days with placebo or AG013925, respectively (Fig. 1A).
Parallel MRI measurements of tumor blood volumes (Vb) in
animals either treated with placebo or with a KDR inhibitor
showed highly statistically significant differences in Vb between
experimental and placebo groups (P < 0.001; Fig. 1B) after two
doses of VEGFR2-TKI administered within 1 day (see also Table 1).
MRI of animals with MV522 xenografts revealed small bilateral
tumors (Fig. 2A and B). The tumor blood supply was visible after
the injection of PGC-Gd (see Fig. 2B , inset). On comparative
histology, tumors in placebo- and VEGFR-TKI–treated groups
appeared similar, with no extensive necrosis or hemorrhage after
two consecutive treatments (Fig. 2C and D). A control intravascular
marker (monocrystalline iron oxide nanoparticles; ref. 35) that
could be easily identified in small concentrations in tissues by
using iron stain showed no leakage into the interstitium, before or
after the treatment (Fig. 2E).
High-resolution MRI of colon-implanted orthotopic tumors at
9.4T, using T2-weighted sequences, showed small tumors visible in
and around the colon on axial images (Fig. 3A , arrow). On cross-
sectional histology of the colon (Fig. 3B), these tumors showed a
close shape similarity to in vivo magnetic resonance images of the
tumors. The T2-weighted images were used for selecting region of
interest for T1-weighted signal measurements that were further
used for calculating Vb values (see Table 1). The presence and
approximate location of these tumors was verified before MRI by
using exploratory endoscopy (Fig. 3C and D). Due to the
expression of DsRed2 marker protein, the location of the tumor
in colon could be unambiguously verified (Fig. 3D). Immunohis-
tology of the tumor invading the colon showed the presence of
many small tumors surrounded by vascularized stroma (Fig. 3E ,
arrows).
Figure 1. Tumor tissue volume and tumor blood volume as predictors of
response to the antiangiogenic treatment. A, tumor volumes measured using
caliper method in animals either treated with 0.5% CMC (placebo groups 1
and 3) or 25 mg AG013925/kg p.o. b.i.d. (experimental groups 2 and 4). Groups
1 and 2 were treated for 24 hours (2 treatments) whereas groups 3 and 4
were treated for 7 days (14 treatments). There was no statistically significant
differences in tissue volumes between experimental and control groups treated
for 1 day (P > 0.2). B, tumor absolute blood volumes (Vb) measured in animal
groups shown in A . There was a highly significant difference in Vb between
experimental and control groups (*, P < 0.001). Columns, mean; bars, SE.
Early Tumor Blood Volume Response to KDR Inhibitor
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Using signal intensity analysis of magnetic resonance images, we
obtained blood volume measurements at different flip angle values
(40j, 60j, and 80j) (Fig. 4A and B). The high flip angle of 80j used
in combination with a very short TE (minimal) and TR = 30 ms
provided an accurate measurement of Vb (23). The data obtained
with three different flip angles allowed to track the dependence
of blood volume on water exchange (i.e., provided information
about the change in vascular barrier function as a result of the
antiangiogenic treatment). Approximately 1 week after the implan-
tation ectopic tumor, Vb was nearly equivalent to that of the
muscle. The mean absolute Vb values determined at 80j were
2.7% and 2.4% of total tissue volume for muscle and tumor,
respectively. In the short-term placebo-treated group, the mea-
sured ratios of the average Vb determined at 40j and 80j flip angles
(R flip) were 1.8 and 1.6 for tumor and muscle, respectively (Fig. 4A).
After a short-term treatment, Vb decreased for all flip angles
(compared with the placebo-treated group, Fig. 4A) and R flip values
Table 1. Tumor blood volume measured in MV522 xenografts by using MRI and radionuclide determination of hematocrit in
tissues of experimental and control animals
Blood volume (Vb),
ectopic tumors, %*
Blood volume (Vb),
orthotopic (colon) tumors, %*
Hematocrit
(%RBC by volume)
Tumorc Musclec Tumor Muscle Tumor Muscle
Placebo 1 d
(2 treatments)
2.4 F 0.1,b n = 20 2.6 F 0.1, n = 14 ND ND 31 F 2,x n = 9 41 F 1, n = 5
Experiment 1 d
(2 treatments)
1.1 F 0.1,b n = 21 3.1 F 0.1, n = 17 ND ND 36 F 1,x n = 9 40.0 F 0.5, n = 5
Placebo 7 d
(14 treatments)
4.2 F 0.1,b n = 20 3.2 F 0.1, n = 16 11.9 F 2.0,x n = 4 3.9 F 0.2, n = 4 ND ND
Experiment 7 d
(14 treatments)
1.1 F 0.1,b n = 18 2.8 F 0.1, n = 23 5.4 F 1.1,x n = 4 3.6 F 0.2, n = 4 ND ND
NOTE: Animals were used for imaging experiments 1 week after the implantation of MV522 cells as described in Materials and Methods. Placebo-treated
mice received 0.5% solution of CMC p.o. b.i.d.; VEGFR2-TKI–treated mice received 25 mg/kg AG013925 suspension in 0.5% CMC p.o. b.i.d. The results are
shown as mean F SE. n , number of MRI slices analyzed per group, or number of animals/group. Statistical significance was determined using Student
unpaired t test with Welch’s correction, ND, not determined.
*Blood volumes measured under the conditions of the highest accuracy.
cMRI results are corrected for RBC content.
bHighly statistically significant differences (P < 0.001).
xStatistically significant differences (P < 0.05).
Figure 2. A representative magnetic resonance image of bilaterally implanted
ectopic MV522 tumors before the injection of PGC-Gd (A) or after the i.v.
injection of PGC-Gd (0.1 mL, 50 Amol Gd/kg, B). The images (matrix = 256 
256, slice thickness = 0.7 mm) were obtained at 1.5 T using three-dimensional
SPGR pulse sequence; TR/TE = 30/4.1 ms and flip angle of 80j. Arrows, tumor
location. A fiduciary standard (a tube filled with a 25 Amol/L GdDTPA solution)
was placed next to the mouse. Inset, a subtraction image showing tumor
vasculature contrasted with PGC-Gd. Bar, 1 cm. C, histology (H&E stain) of
MV522 tumor (placebo-treated); D, histology (H&E stain) of VEGFR2-TKI
(AG01395, 25 mg/kg)–treated tumor; E, frozen section of VEGFR2-TKI treated
tumor obtained after the i.v. injection of monocrystalline iron oxide nanoparticles
(5 mg iron/kg) to delineate perfused blood vessels. Arrow, iron-positive Perl’s
stain. Bar, 200 Am.
Figure 3. Imaging and histology of orthotopic MV522-DsRed2 colon carcinoma.
A, MRI of orthotopic MV522-DsRed2 tumor implanted into the colon wall.
A T2-weighted image obtained at 9.4T (TR/TE = 3,000/30 ms) is shown. Arrow,
tumor in the colon. B, histology (H&E stain) of MV522-DsRed2 tumor dissected
from placebo-treated animal. C, visible light image of the tumor obtained by
using a microendoscope before treatment. D, fluorescence image of the field
presented in C obtained by exciting fluorescence of DsRed2 using a 300-W
Xenon lamp source. E, histology of small tumor deposits in the colon wall.
Arrowheads, CD31-positive microvessels in the stroma. Bar, 200 Am.
Cancer Research
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were 1.5 for muscle and 1.1 for tumor. Only in treated tumors there
was a substantial suppression of water exchange across the
vascular barrier (Fig. 4A) because linear approximation of Vb
dependence on the flip angle showed a highly attenuated negative
slope in comparison with the control tumors. The above linear
fitting was valid only at high flip angles (above 40j) used for
imaging in this study.
In the placebo-treated group (1 week, group 3), Vb was
considerably higher than that of the muscle for flip angles <80j
(Fig. 4B). The ratio of Vb values obtained at 40j and 80j flip angles
was much higher for the tumor than for the muscle (R flip = 2.39 and
1.36, respectively). The high negative slope value (0.14) for placebo-
treated tumor (Fig. 4B) suggested faster water exchange across
vascular barriers in tumor vessels. In contrast, in a group of mice
treated with VEGFR2-TKI for 7 days (group 4), the measured tumor
Vb was significantly lower than that of the muscle (Fig. 4B). The flip
angle dependence of Vb in these animals was similar to that of the
muscle. The Vb value was nearly constant at all flip angles (negative
slope, 0.004), indicating suppression of water exchange (i.e.,
similar to 1-day treated tumors). In orthotopic tumor–bearing
animals treated for 7 days with VEGFR2-TKI, a statistically
significant (P < 0.05) 2-fold decrease of measured Vb was detected
when compared with placebo-treated animals (Table 1). As in the
case of ectopic tumor model, no significant changes of Vb in the
muscle were observed. Tumor Vb values measured in mouse
orthotopic models were much higher than Vb in s.c. ectopic tumors
(11.9 F 2.0% versus 4.2 F 0.1%).
Radionuclide measurements of RBC fractions in tumors and
muscle. The main goal of the radionuclide study was to obtain
Figure 4. Water exchange rate changes in tumors after the KDR treatment.
A, absolute blood volume measurements; two doses: control placebo-treated
mice (group 1: x, tumors; n, muscle) and AG01395-treated mice (group 2:
E, tumors; ., muscle). B, absolute blood volume (Vb) measurements;
14 doses: control placebo-treated mice (group 3: x, tumors; n, muscle) and
AG01395-treated mice (group 4, E, tumors; ., muscle) using MRI as
described in Materials and Methods. Mice were treated p.o. b.i.d. with 25 mg
AG013925/kg in 0.5% CMC or 0.5% CMC alone (placebo). A dependence of
Vb from flip angle in three-dimensional SPGR pulse sequence is shown.
This dependence reflects water exchange rate across the vascular barrier.
Negative slopes of the curves are shown at the right. The higher value of the
slope corresponds to a faster water exchange. Measurements obtained at a flip
angle of 80j resulted in the most accurate Vb value. Points, mean; bars, SE.
Figure 5. Histology of control tumors (placebo-treated, group 1) obtained
from animals injected with Alexa 488–labeled L. esculentum lectin.
A, low-magnification fluorescence microscopy of TUNEL staining of MV522
tumor section; B, low-magnification microscopy of fluorescent lectin staining of
blood vessels reflecting vascular density. Bar, 400 Am. C, dual-channel
fluorescence microscopy depicting lectin binding (green ) to vessel-lining cells
and TUNEL staining of apoptotic cells; D, anti-CD31 staining (microvascular
density staining) of blood vessels in control, placebo-treated MV522 tumor
followed by H&E staining. Bar, 100 Am.
Early Tumor Blood Volume Response to KDR Inhibitor
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correction factors to account for potential differences in tissue
concentration of PGC-Gd (Table 1) by determining RBC content in
blood circulating in tumors or normal muscle, respectively. We
used 99mTc-labeled RBC as markers of blood cell volume fraction.
Because PGC-Gd is excluded from RBCs, the local concentration of
RBC could affect tissue magnetic resonance signal intensity change
after the contrast agent injection due to the dilution of PGC-Gd in
the plasma by RBCs. By measuring RBC fractions in blood, we
accounted for possible measurement error due to the tissue-
dependent volume ratio differences between plasma and RBC
fractions. As determined by standard hematocrit counting
methods, nu/nu mice had RBC fraction of 0.4 (40% hematocrit,
Table 1). The RBC volume fraction in tumors was only 75% of
muscle in the placebo-treated group. However, in the treated group
of animals, the tumor blood RBC fraction was nearly equivalent to
that of the muscle. We found that the difference between corrected
and experimental Vb values was negligibly small in treated animals.
In placebo-treated mice, experimental Vb values for tumors were
significantly different from corrected Vb because of the reduced
RBC fraction in tumoral circulation.
Histology. To determine whether the measured changes in blood
volume were reflecting changes in tumor vascular density and
vascular architecture, we did histology of tumors. After in vivo
injection of fucose-specific fluorescent-labeled lectin (Figs. 5–7), we
observed bright fluorescence of vascular wall. In parallel, TUNEL
staining of histology sections was done. The numbers of fluorescent
(apoptotic) nuclei were relatively low in MV522 placebo-treated
tumors (7 F 3 cells/mm2 tumor section area, Fig. 5A). The density
of perfused microvessels in these tumors was very high (69 F 20
lectin-positive vessels/mm2 tumor section area, Fig. 5B). Similar
vascular density counts were obtained by using anti-CD31 anti-
bodies (80 F 22 vessels/mm2). Blood vessels appeared dilated and
highly positive for fluorescent lectin (Fig. 5C). The difference
between microvascular density counts obtained using in vivo
fluorescent lectin labeling and anti-CD31 staining (Fig. 5D) did not
exceed 16%. If compared with the placebo group, VEGFR2-TKI
treatment resulted in a 7-fold increase in the number of TUNEL-
positive cells (48F 6 cells/mm2, Fig. 6A). This increase paralleled an
average of a 3-fold decrease of the blood vessel density (20 F 10
vessel/mm2, Fig. 6B and E). Normal muscle adjacent to the tumor
showed intact vascularity (Fig. 6D). However, blood vessels at the
border of the tumor and muscle contained TUNEL-positive cells
lining lectin-positive vessels (Fig. 6D). Endothelial cell death was also
observed in some small-diameter vessels on the periphery of tumors
that were stained positively for DNA fragmentation and lectin
(Fig. 7A and B , arrows). Histology of tumors after a 7-day treatment
revealed regions of apoptosis. The areas of tumor cell death seemed
to be more extensive than that of 2-day treated tumors. Apoptosis-
free areas of tumors were sustained by a few small-diameter vessels
that were positive for lectin and anti-CD31 antibody (Fig. 7C).
Discussion
Noninvasive imaging of blood volume changes in tumors as
well as tumoral vascular permeability measurements enable the
assessment of antiangiogenic (or angiostatic) therapies in live
animals (reviewed in ref. 16). It has been suggested that tumor
blood volume monitoring in preclinical and clinical research could
be valuable for detecting early changes of tumor homeostasis
mediated by antiangiogenesis drugs and in predicting the response
of cancer to a specific type of drug treatment as has been shown in
the case of combretastatin (36) or dexamethasone (37).
We report here noninvasive imaging analysis of the antiangio-
genic effects of a VEGFR2-TKI in ectopic as well as orthotopic
MV522 xenograft tumor models. We anticipated that the inhibitor
was capable of inducing dramatic changes in tumor blood supply
at the very early phase of the treatment. Our decision to explore
blood volume changes rather than vascular permeability was due
to the anticipated strong antitumor effects of VEGFR2-TKI.
Vascular collapse as a result of endothelial cell death or tumor
vessel regression (10) drastically decreases the overall vascular area
in the tumor, especially in the tumor periphery (38). The above
Figure 7. TUNEL analysis of MV522 tumors. A and B, representative
micrographs of tumor peripheral vessels showing apoptosis of vessel-lining cells.
Arrows, cells morphologically similar to endothelial cells stained with Alexa
488–labeled L. esculentum lectin. *, vascular lumena. Bar, 50 Am. C, fluorescent
image depicting a section of 7-day treated MV522 tumor showing areas of cell
death (red) and surviving blood vessels (green ). Bar, 100 Am.
Figure 6. Histology of MV522 tumors treated with antiangiogenic VEGFR2-TKI
AG01395, 25 mg/kg p.o. (group 2) obtained from animals injected with Alexa
488–labeled L. esculentum lectin (A -D ). Images were obtained using
fluorescence microscopy of tumors. A, low-magnification microscopy of TUNEL
staining of tumor section. B, low-magnification microscopy of fluorescent lectin
staining of blood vessels reflecting vascular density. A and B , bar = 400 Am.
C, dual-channel fluorescence microscopy depicting lectin binding (green ) to
vessel-lining cells and TUNEL staining of apoptotic cells. D, fluorescent image of
the tumor/muscle interface showing a blood vessel with TUNEL-positive cells.
Note the high density of vascularization of the muscle and nearly absent
vascularization of the treated tumor. E, anti-CD31 staining (microvascular
density staining) of blood vessels in VEGFR2-TKI–treated MV522 tumor followed
by H&E staining. Animals were treated with two doses at 25 mg/kg with 12-hour
interval in between the treatments. C to E , bar = 100 Am.
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effect would make it impossible to compare the relative changes of
vascular permeability in the tumor (‘‘permeability-surface area
product’’; refs. 39–41) before and after the treatment. Therefore, we
imaged tumor blood volume using MRI enhanced with a long-
circulating, biocompatible, and nontoxic paramagnetic T1 contrast
agent (PGC; ref. 27). This contrast agent is known to selectively
decrease relaxation times of water protons in the vascular
compartment without any initial leakage from blood vessels due
to a large hydrodynamic diameter corresponding to a globular
protein of 1,500 kDa (42).
The analysis of MRI results was valid under the following
assumptions: (a) the movement of protons between extracellular
and cellular compartments in the blood was considered rapid
allowing to treat RBC and plasma as one vascular space (two-
compartment Hazelwood model; ref. 23); (b) the kinetics of
extravascular-intravascular water exchange was slower or compa-
rable to the time required to obtain an image within the selected
tissue volume; (c) there was no appreciable leakage of the
paramagnetic probe (PGC-Gd) into the interstitium of tumors
during the imaging experiment (23, 25, 42). The latter assumption
was confirmed by using a model nanoparticle agent (see Fig. 2).
By comparing initial tumor volume data with the results of Vb
measurements, we observed that unlike tumor tissue volume
(Fig. 1A), tumor blood volume (Fig. 1B) responded dramatically
to VEGFR2-TKI showing a decrease at the very early phase of
treatment (i.e., after two doses of the antiangiogenic drug).
Furthermore, the analysis of vascular water exchange rates in
tissues of control and treated animals, by examining the
measurement dependency of Vb on flip angle (33), suggested a
tissue-dependent disparity in water exchange rates across the
vascular membrane in the muscle and the nearby tumor. Both Vb
and water exchange rate were maintained at the low levels over the
course of the treatments, suggesting the effective suppression of
angiogenesis by VEGFR2-TKI (see Fig. 4).
The exclusion of paramagnetic PGC-Gd from RBC in local
circulation could potentially introduce tissue-dependent measure-
ment inaccuracies due to local differences in blood composition in
normal and tumor blood vessels. The radioisotope-labeled RBC
study showed an increase of RBC fraction in the remaining blood
supply of the tumors after the treatment, whereas RBC fraction in
the muscle remained constant (Table 1). The low tumoral RBC
fraction in placebo-treated mice was probably caused by abnormal
architecture of the neovasculature. The increase of RBC content in
blood supply of treated tumors suggests that after the VEGFR2-TKI
treatment, tumor neovasculature undergoes partial ‘‘normaliza-
tion,’’ a general effect observed by intravital microscopy after
various antiangiogenic treatments (43, 44). Alternatively, the above
results may indicate that there is a fraction of co-opted tumor
vessels that exhibit a very low degree of endothelial proliferation
(45). These vessels could be spared from regression as a result
of antiangiogenic treatment or VEGF withdrawal (46). In the case
of VEGFR2-TKI treatment, the latter scenario seems probable.
It should be noted that in orthotopic MV522-DsRed2 tumors,
VEGFR2-TKI resulted in a lesser relative Vb decrease if compared
with their ectopic counterparts. This could be explained by the
tumor-mediated co-option of preexisting vessels (47) as opposed to
de novo angiogenesis and, consequently, a lack of susceptibility of
these vessels to treatments that affect predominantly proliferating
endothelial cells. Histology of treated and control tumors revealed
that surviving vessels were present in treated tumors in very small
numbers (Fig. 6). The observed drastic decrease of blood supply
(compare Figs. 5 and 6) suggested that rapid and extensive
apoptosis of tumor cells could be explained either by permanent or
transient interruption of vascular perfusion resulting from
VEGFR2-TKI treatment. The treatment resulted in endothelial
apoptosis. Although in majority of histology sections endothelial
apoptosis could not be differentiated from tumor cell death, some
of the remaining vessels on tumor periphery showed an evidence
of vessel-lining cell apoptosis, which seems to correlate with
antiangiogenic treatment (Figs. 6D and 7A-B). Whereas some of
the TUNEL-positive cells resemble endothelial cells (Fig. 7A and B),
VEGFR2-TKI could cause death in cells besides endothelial cells
(e.g., pericytes or other mural cells as well as stromal fibroblasts
expressing PDGF receptor h; ref. 5). The prolonged treatment of
tumor-bearing animals with VEGFR2-TKI suggested that some of
the remaining tumor blood vessels were perfused and provided
survival of the adjacent tumor cells (Fig. 7C) but did not allow
tumor expansion (Fig. 1).
In conclusion, quantitative MRI enabled noninvasive monitoring
of the longitudinal changes in tumor blood volume that responded
very early to antiangiogenic therapy with VEGFR2-TKI. The
decrease of Vb was tumor specific and concomitant to massive
tumor cell/endothelial apoptosis, decrease of vascular density, and
increase of RBC content in the residual tumor blood supply. The
MRI-assisted analysis of Vb could be an important adjunct in
evaluating antiangiogenic therapies in preclinical research and
clinical practice.
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